What is Sparrow Pharmaceuticals?
Sparrow Pharmaceuticals is dedicated to developing innovative targeted therapies for metabolic diseases, with a primary focus on its lead candidate, clofutriben. This HSD-1 inhibitor is engineered to reduce intracellular cortisol levels, aiming to improve patient outcomes in challenging cases of type 2 diabetes and associated conditions. The company's strategic approach involves leveraging scientific advancements to address unmet medical needs within the metabolic disease landscape, positioning itself as a key player in this therapeutic area.
How much funding has Sparrow Pharmaceuticals raised?
Sparrow Pharmaceuticals has raised a total of $206.8M across 3 funding rounds:
Series A
$50M
Private Equity
$61.8M
Series B
$95M
Series A (2021): $50M with participation from RiverVest Venture Partners, US Venture Partners, and OrbiMed
Private Equity (2025): $61.8M, investors not publicly disclosed
Series B (2025): $95M supported by OrbiMed, US Venture Partners, Forbion, RiverVest Venture Partners, and RA Capital Management
Key Investors in Sparrow Pharmaceuticals
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health. They support companies at various development stages with deep expertise in life sciences and healthcare business development.
US Venture Partners
U.S. Venture Partners (USVP) is a prominent Silicon Valley venture capital firm specializing in early-stage investments across cybersecurity, enterprise software, consumer products, and healthcare. They leverage a strong network to support company scaling and product development.
Forbion
Forbion is a leading European venture capital firm that assists companies in bridging research and development through its expertise in drug development and company building. They are signatories to the UN Principles for Responsible Investment.
What's next for Sparrow Pharmaceuticals?
The substantial enterprise-level funding and recent strategic investment signal Sparrow Pharmaceuticals' readiness to advance its clinical programs and potentially scale its operations. This capital infusion is expected to accelerate the development of clofutriben through critical clinical trial phases and support broader research initiatives. The company's ability to attract significant backing from prominent healthcare investors suggests a strong belief in its therapeutic approach and market potential, paving the way for future growth and potential commercialization.
See full Sparrow Pharmaceuticals company page
